Will Pralsetinib be included in medical insurance in 2024?

Pralsetinib (Pralsetinib) is a once-daily oral targeted therapy approved by the U.S. Food and Drug Administration (FDA). Platinib has been approved by the National Medical Products Administration and is sold in China as Platinib Capsules (Pujihua/GAVRETO). In clinical studies of Platinib, it was well tolerated. It is believed that Platinib Capsules will be included in the national medical insurance in the near future to reduce the burden on patients in need.

Platinib is used to treat three indications: For the treatment of adult patients with locally advanced or metastaticRET fusion-positive non-small cell lung cancer (NSCLC) after receiving platinum-based chemotherapy; requiring systemic therapy pan>Adult and pediatric patients 12 years and older with advanced or metastatic RET-mutated medullary thyroid cancer (MTC); and adults and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and are refractory to radioactive iodine therapy (if radioactive iodine therapy is appropriate).

Currently, the price of Platinib’s original drug, which is currently on the domestic market, may be around RMB 60,000 for a box of 120 pills. The price of the European version of Platinib's original drug sold overseas may be around RMB 40,000 per box of 60 pills, and the U.S. version may be priced around RMB 150,000 per box (the price may fluctuate due to exchange rates), which is expensive. There are also generic Platinib drugs available for sale overseas. The ingredients of the drug are basically the same as those of the original drug at home and abroad. The price of 120 pills per box may be more than RMB 4,000 (the price may fluctuate due to the exchange rate).